10-K: Neogen Reports Over $1 Billion Net Loss Amidst Massive Goodwill Impairment and Revenue Decline

Neogen Corporation announced a significant net loss of over $1 billion for fiscal year 2025, primarily driven by substantial goodwill impairment charges and a decrease in total revenues across its Food Safety and Animal Safety segments.

Summary

• Total revenues for fiscal year 2025 decreased by $29.6 million (3%) to $894.7 million, compared to $924.2 million in fiscal year 2024.
• A net loss of $1,092.0 million was reported for fiscal year 2025, a substantial increase from a net loss of $9.4 million in the prior fiscal year.
• Goodwill impairment charges totaled $1,059.3 million in fiscal year 2025, with $1,045.3 million attributed to the Food Safety segment and $13.1 million to the Animal Safety segment.
• Gross margin declined to 47.1% in fiscal year 2025 from 50.2% in the prior year, impacted by lower volume, higher manufacturing costs, elevated inventory write-offs, and tariffs.
• Food Safety segment revenues decreased by $17.2 million (3%) to $638.1 million, primarily due to $24.0 million in currency headwinds and production constraints in sample collection products.
• Animal Safety segment revenues decreased by $12.4 million (5%) to $256.5 million, driven by lower genomics volume (due to restructuring, companion animal market weakness, and customer insourcing) and reduced sales of insect control and veterinary instruments.
• International revenues accounted for 50.2% of total revenues in fiscal year 2025, experiencing a $24.3 million currency headwind.
• The company completed a refinancing of its Term Loan and revolving line of credit on April 4, 2025, lowering the interest rate spread.
• An agreement to sell the global Cleaners and Disinfectants business to Kersia Group for $130.0 million in cash, plus contingent consideration, was announced in April 2025 and closed on July 18, 2025, with proceeds intended for debt repayment.
• Management identified new material weaknesses in internal control over financial reporting as of May 31, 2025, related to control activities and information/communication, leading to an adverse opinion from the independent auditor.
• Previously identified material weaknesses in internal control over financial reporting related to IT general controls and period-end invoice accruals were remediated as of May 31, 2025.

Sentiment

Score: 2

Explanation: The significant net loss exceeding $1 billion, primarily due to a massive goodwill impairment, coupled with declining revenues and newly identified material weaknesses in internal controls leading to an adverse auditor opinion, indicates a very negative financial performance and raises serious concerns about the company's operational and financial health. While strategic actions like debt refinancing and a divestiture are noted, they do not offset the severity of the reported losses and control deficiencies.

Positives

• Achieved growth in indicator testing, pathogens, and biosecurity product lines within the Food Safety segment.
• Successfully introduced new products in the food quality and nutritional analysis product line in the US and Canada.
• Resolved most production delays for the sample collection product line in the second half of fiscal year 2025, with production returning to prior normal levels.
• Experienced growth in the bovine market within genomics services, partially offsetting declines in other areas.
• Successfully refinanced the Term Loan and revolving line of credit, resulting in a lower interest rate spread from 2.35% to 1.75%.
• Completed the divestiture of the global Cleaners and Disinfectants business for $130.0 million in cash, with proceeds earmarked for debt repayment.
• Remediation efforts for previously identified material weaknesses in internal control over financial reporting were effective as of May 31, 2025.
• Maintained compliance with all financial covenants under the Credit Facilities as of May 31, 2025.

Negatives

• Reported a significant net loss of $1,092.0 million for fiscal year 2025.
• Incurred a substantial goodwill impairment charge of $1,059.3 million in fiscal year 2025.
• Total revenues decreased by 3% year-over-year, impacted by a $24.3 million unfavorable foreign exchange rate and $3.9 million from discontinued product lines.
• Gross margin declined to 47.1% from 50.2% due to lower volume, higher manufacturing costs, elevated inventory write-offs, and tariffs.
• Experienced production constraints impacting the sample collection product line and significant production inefficiencies after relocation.
• Noted lower sales of veterinary instruments due to a customer sourcing move based on geographical preference.
• Observed lower genomics volume due to voluntary attrition from restructuring actions, weakness in the companion animal market, and higher customer insourcing.
• Identified new material weaknesses in internal control over financial reporting related to control activities and information/communication as of May 31, 2025.
• The independent registered public accounting firm issued an adverse opinion on the effectiveness of internal control over financial reporting.
• Increased corporate expenses due to additional headcount, contracted services, and higher costs associated with the prior year's enterprise resource planning system implementation.
• Experienced negative impacts from increased tariffs and ongoing geopolitical tensions (Russia-Ukraine, Middle East conflicts) on material costs, transportation, energy, and raw materials.

Risks

• Failure to realize anticipated financial and other benefits, including growth opportunities, from the 3M Food Safety merger transaction, particularly in integrating manufacturing operations.
• Potential for future impairment charges related to the 3M Food Safety business integration.
• Restrictions on Neogen Food Safety Switzerland's actions until September 1, 2025, could impair the ability to implement strategic initiatives due to tax treatment requirements.
• Adverse effects from tariffs and other trade measures, which could increase material input costs and soften demand for products.
• Exposure to political, social, and economic instability, government export controls, and currency fluctuations in international operations.
• Continued impact of the Russia-Ukraine and Middle East conflicts on raw material prices, availability, sales, and earnings.
• Material weaknesses in internal control over financial reporting could prevent accurate financial reporting and lead to material misstatements.
• Inability to successfully promote internal growth and identify/integrate future acquisitions.
• Reliance on information systems infrastructure, with risks of security breaches or system failures damaging reputation and operations.
• Disruption of manufacturing and service operations due to catastrophic events like fire, flood, or natural disasters.
• Dependence on third-party package delivery services, with risks of disruptions or price increases.
• Reliance on third-party suppliers, including single-source suppliers, which could lead to supply disruptions and higher costs.
• Dependence on distributors, which presents risks if relationships are not maintained or if distributors promote competitors' products.
• Inability to develop new products and technologies, which could impair competitive position and reduce sales.
• Failure to maintain a positive reputation or conduct effective sales and marketing activities.
• Significant increases in raw material costs or inability to obtain necessary raw materials.
• Risks associated with improper conduct by employees, agents, or business partners, and compliance burdens with anti-bribery and anti-corruption laws.
• Changes in domestic and foreign laws, regulations, policies, and enforcement initiatives increasing compliance costs.
• Differences in and changes to tax rates in various jurisdictions and unanticipated outcomes from tax audits.
• Deterioration in future expected profitability or cash flows could result in further impairment of goodwill and intangible assets.
• Intense competition in the food and animal safety industries from companies with greater financial resources.
• Dependence on the agricultural marketplace, which is affected by factors beyond control such as weather and commodity prices.
• Substantial indebtedness and related debt service obligations, which could reduce financial flexibility and increase vulnerability to interest rate increases.
• Potential violation of financial or other covenants in credit agreements.
• Uncertainty of outcomes from litigation and other legal proceedings, potentially leading to losses in excess of current expectations.
• Significant fluctuations in quarterly and annual operating results.
• High volatility in the market price of common stock.
• Inability to obtain or maintain protection for intellectual property, or facing patent infringement challenges.
• Substantial governmental regulation affecting products and facilities, with potential for increased compliance costs.
• Failure to attract, retain, and develop qualified personnel, including for key management positions.
• Exposure to product or service liability claims.
• Changing political conditions in markets where the company operates.
• Impacts of climate change, or legal/regulatory measures to address it, on operations and costs.
• Inability to meet stakeholder expectations related to environmental, social, and governance (ESG) objectives.
• Adverse effects of new tax legislation (e.g., OECD Pillar Two, OBBBA) on financial results and tax liabilities.

Future Outlook

The company anticipates continued impacts from economic headwinds, geopolitical tensions, and internal operational issues in fiscal year 2026. Management is optimistic about potential future revenue growth in the Animal Safety segment, particularly if distribution channels begin to restock inventory. Research and development expenditures are expected to remain at 2% to 3% of total revenues annually, with new products anticipated for commercial availability in fiscal years 2026 and 2027. Capital expenditures for fiscal year 2026 are estimated at approximately $50 million, largely for the integration of acquired 3M Food Safety products and new manufacturing facilities.

Management Comments

• Our mission is to be the leading company in fueling a brighter future for global food security.
• Management currently expects our future research and development expenditures to approximate 2% to 3% of total revenues annually.
• Management expects that a number of these products will be commercially available at various times during fiscal years 2026 and 2027.
• We continue to evaluate the nature and extent to which these issues impact our business, including consolidated results of operations, financial condition and liquidity. We expect these issues to continue to impact us in fiscal year 2026.
• We are optimistic about potential future revenue growth in the segment, particularly if the distribution channel begins to meaningfully restock inventory.
• We believe that our cash flows from operations, cash on hand, and borrowing capacity will enable us to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development, and execute our strategic plans.
• In the opinion of our management, the outcome of such proceedings and other litigation currently pending will not materially affect our consolidated operations, cash flows, or financial position.

Industry Context

The food safety industry is experiencing lower food production due to the cumulative effect of recent significant inflation, particularly in food prices. The animal safety end market is currently at or near cyclical lows, and the companion animal market is facing weakness due to inflation, fewer pet adoptions, and increased customer in-sourcing. The company operates within highly competitive industries characterized by rapid technological changes and intense competition from both smaller businesses and large multinational corporations. Global cybersecurity threats are increasing, and the agricultural sector, which is a primary customer base, remains susceptible to external factors like weather and commodity price fluctuations.

Comparison to Industry Standards

• The company competes primarily on the basis of ease of use, speed, accuracy, and other performance characteristics of its products, rather than solely on price.
• Neogen Genomics is described as a leading worldwide commercial animal genomics laboratory, utilizing cutting-edge technology to accelerate genetic improvement.
• The company markets BotVax B, which is noted as the only USDA-approved vaccine for the prevention of Type B botulism in horses.
• Safety programs have resulted in strong safety performance, implying adherence to or exceeding industry safety standards, though specific benchmarks are not provided.

Management Changes

Corporate Governance

Legal Proceedings

• Routinely involved in legal proceedings and litigation arising in the ordinary course of business, with management believing current pending matters will not materially affect consolidated operations, cash flows, or financial position.
• Ongoing environmental remediation and monitoring activities at the Randolph, Wisconsin manufacturing facility, with an estimated remaining liability of $916 thousand over 15 years.
• A gain of $2,700 thousand was recorded related to a settlement regarding the prior acquisition of certain fixed assets, partially offset by a related fixed asset impairment of $2,055 thousand.
• A loss of $1,400 thousand was recorded related to an updated valuation of the performance milestone liability for the CAPInnoVet, Inc. transaction.
• A liability of $930 thousand related to a contingent liability from the Corvium, Inc. transaction was reversed as the final milestone payment was not achieved.
• Received $1,265 thousand of business interruption insurance proceeds in fiscal year 2024 relating to fire damage at a genomics lab facility.
• An investigation by the U.S. Treasury Department's Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran was concluded in the fourth quarter of fiscal year 2023 without civil monetary penalty or other enforcement action, leading to the reversal of a $600 thousand accrual.
• Royalty expense for licensed technologies amounted to $1,605 thousand in fiscal year 2025, $3,250 thousand in fiscal year 2024, and $3,392 thousand in fiscal year 2023, with future minimum royalty payments scheduled.

Stakeholder Impact

• Shareholders: Experienced a significant net loss and goodwill impairment, negatively impacting shareholder equity. The stock price is subject to high volatility, and the company has no current plans to pay dividends.
• Employees: The company employed 2,974 people worldwide as of May 31, 2025. Restructuring actions in the genomics business led to voluntary attrition. The company is committed to employee development, compensation, benefits, health, and safety. A new President and CEO was appointed.
• Customers: Faced shipment delays due to ERP system implementation and the transition from 3M, leading to lost market share. Production constraints impacted the availability of sample collection products, and a customer sourcing move affected veterinary instrument sales.
• Suppliers: The company's dependence on third-party and single-source suppliers creates risks of supply disruptions and increased costs.
• Creditors: The company has substantial indebtedness but was in compliance with all financial covenants as of May 31, 2025. Proceeds from the divestiture of the Cleaners and Disinfectants business will be used to repay debt.

Next Steps

• Continue the integration of the 3M Food Safety business, with a particular focus on manufacturing operations.
• Implement and evaluate measures to remediate identified material weaknesses in internal control over financial reporting.
• Develop and commercialize several new and improved diagnostic tests and complementary products during fiscal years 2026 and 2027.
• Transition to in-house manufacturing of Petrifilm products.
• Expand markets by fostering increased use of products by existing customers.
• Strengthen operations and sales and marketing activities in international geographies.
• Identify and complete strategic acquisitions that enhance existing product categories or create new products/services.
• Proceed with estimated capital expenditures of approximately $50 million in fiscal year 2026, including $35 million for the construction of a new manufacturing facility in Lansing, Michigan.
• Monitor and evaluate the impact of the OECD Pillar 2 global minimum tax rules and the One Big Beautiful Bill Act (OBBBA) on future tax rates and liabilities.
• Begin required quarterly principal payments on the term loan facility in November 2025.
• Adopt interim requirements for Segment Reporting (ASU 2023-07) on June 1, 2025.
• Evaluate the impact of ASU 2023-09 (Income Taxes) for annual periods beginning after December 15, 2024.
• Evaluate the impact of ASU No. 2024-03 (Expense Disaggregation) for annual reporting periods beginning after December 15, 2026.

Key Dates

Recommendation

The substantial net loss of over $1 billion, primarily driven by a massive goodwill impairment charge, signals significant underlying issues with asset valuation and potentially the long-term profitability of acquired businesses. The decline in revenue across both core segments, coupled with ongoing operational inefficiencies, supply chain challenges, and elevated inventory write-offs, indicates a deteriorating financial performance. Furthermore, the identification of new material weaknesses in internal controls over financial reporting, leading to an adverse auditor opinion, raises serious concerns about the reliability of financial reporting and corporate governance. While debt refinancing and a divestiture are positive strategic moves, they do not outweigh the fundamental financial and operational challenges highlighted in this filing. A seasoned investor would likely view these issues as a strong signal to divest, given the significant risks and poor financial results.

Keywords

Food Safety, Animal Safety, Diagnostic Test Kits, Genomics, Goodwill Impairment, SEC Filing, 10-K, Financial Results, Internal Controls, Debt Refinancing, Divestiture, Supply Chain, International Sales, Corporate Governance, Risk Management, Nasdaq, NEOG, Mycotoxins, Pathogens, Allergens, Veterinary Instruments, Pharmaceuticals, Vaccines, Rodent Control, Disinfectants